Craig W. Philips is Chief Financial Officer and a Member of the Board of Directors for CounterX Therapeutics, Inc.  He has over thirty five years of pharmaceutical industry experience at both Fortune 500 pharmaceutical and smaller biotech companies and has broad based experience with clinical and commercial operations as well as transactional and fund raising experience.

Previously, Mr. Philips served as President of Kineta Inc a Seattle based biotech company focused on immuno-oncology. In his 10 years with Kineta the company went public through a reverse merger and completed 10 partnering transactions. He was President at CTI Biopharma a NASDAQ listed clinical and commercial stage oncology company where he led the commercial and development activities in the US and EU. Previously, Mr. Philips spent over 20 years with leading biopharmaceutical companies and held strategic and operational leadership roles in the US, Asia, Australia and Europe. He has spent the majority of his career in the clinical and commercial development of specialty pharmaceuticals including the launch of four pharmaceutical products which each exceeded $1 billion in sales.

Mr. Philips sits on the board of several private biotech companies including PharmaIn Corporation and Abacus Bioscience, he is also a Board member of Life Science Washington and was previously a commercial advisor to the Fred Hutchinson Cancer Research Center and the University of Washington. He was a founder of several specialty pharma biotech companies including Abacus Bioscience and PVP Biologics (sold to Takeda).  He received a BS in Business Administration and an MBA from The Ohio State University.